SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of the earliest event reported):
February 26, 2004
NEUROCRINE BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)
| DELAWARE | 0-28150 | 33-0525145 |
| (State or other jurisdiction of | (Commission File Number) | (IRS Employer Identification No.) |
| incorporation or organization) |
| 10555 Science Center Drive, San Diego, CA | 92121 |
| (Address of principal executive offieces) | (Zip Code) |
Registrant’s telephone number, including area code: (858) 658-7600
N/A
(Former name or former address, if changed since last report.)
This Current Report on Form 8-K is filed by Neurocrine Biosciences, Inc., a Delaware corporation (the “Company”), in connection with the matters described herein.
On February 26, 2004, the Company announced the purchase of Wyeth's entire financial interest in indiplon, the Company's late stage clinical development compound for the treatment of insomnia. A press release related to this is attached to this report as Exhibit 99.1 and incorporated herein by reference.
| (c) | EXHIBITS. The following exhibits are filed herewith: | |||
| Exhibit | ||||
| Number | Description of Exhibit | |||
| 99.1 | Press Release dated February 26, 2004 | |||
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| Dated: | February 26, 2004 | /s/ |
Paul W. Hawran |
|
| Paul W. Hawran | ||||
| Executive Vice President | ||||
| and Chief Financial Officer |
2